文献速递头痛与眩晕

依瑞奈单抗治疗慢性偏头痛非阿片类药物过度使用性头痛的疗效与安全性:一项4期随机安慰剂对照试验

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.
PubMed 文献 · JAMA Neurol · 2024-09-16

这项在67个中心开展的随机双盲安慰剂对照试验纳入620例慢性偏头痛伴药物过度使用性头痛(CM-MOH)成人患者,其中非阿片类队列584例。治疗24周后,第6个月时依瑞奈单抗140 mg组MOH缓解率69.1%(OR 2.01 vs 安慰剂,P<.001),70 mg组60.3%(OR 1.37,P=.13),安慰剂组52.6%。依瑞奈单抗140 mg和70 mg组每月急性头痛用药天数较基线分别减少9.4天和7.8天,均优于安慰剂的6.6天。

要点

  • 依瑞奈单抗140 mg每月一次治疗6个月可使非阿片类CM-MOH患者MOH缓解率显著高于安慰剂。
  • 依瑞奈单抗140 mg组每月急性头痛用药天数较基线减少9.4天,安慰剂组减少6.6天,差异-2.7天。
  • 依瑞奈单抗安全性特征与已知一致,最常见治疗中出现的不良事件为便秘15.2%和COVID-19 13.9%。

核心结论

  • 每月注射依瑞奈单抗140 mg可在6个月内安全有效地使非阿片类CM-MOH患者达到MOH缓解。

研究设计与样本

  • 随机、双盲、平行组、安慰剂对照试验,2019年10月7日至2022年11月2日在北美、欧洲和澳大利亚67个中心开展。
  • 筛查992例,入组620例(非阿片类队列584例,阿片类队列36例);主要分析人群为非阿片类队列584例。
  • 干预为依瑞奈单抗70 mg、140 mg或安慰剂,每月一次,共24周。

主要发现

  • 第6个月MOH缓解:依瑞奈单抗140 mg组134例(69.1%)vs 安慰剂组102例(52.6%),OR 2.01(95%CI 1.33-3.05),P<.001。
  • 第6个月MOH缓解:依瑞奈单抗70 mg组117例(60.3%)vs 安慰剂组102例(52.6%),OR 1.37(95%CI 0.92-2.05),P=.13。
  • 每月急性头痛用药天数较基线最小二乘均值变化:依瑞奈单抗140 mg组-9.4天(标准误0.4),与安慰剂差异-2.7天(95%CI -3.9至-1.6),P<.001。
  • 每月急性头痛用药天数较基线最小二乘均值变化:依瑞奈单抗70 mg组-7.8天(标准误0.4),与安慰剂差异-1.2天(95%CI -2.4至-0.1),P=.03;安慰剂组-6.6天(标准误0.4)。
  • 整个双盲治疗期间持续MOH缓解:依瑞奈单抗140 mg组119例(61.3%),70 mg组96例(49.5%),安慰剂组73例(37.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH. OBJECTIVE: To assess erenumab efficacy and safety in patients with nonopioid CM-MOH. DESIGN, SETTINGS, AND PARTICIPANTS: This randomized, double-blind, parallel-group, placebo-controlled trial took place at 67 centers in North America, Europe, and Australia from October 7, 2019, to November 2, 2022. This report reflects the primary analysis conducted in January 2023, using a database snapshot from December 1, 2022, which contains the complete dataset of the double-blind treatment period (DBTP). Participants included adults with CM-MOH who had 1 or more preventive treatment failure(s). There were 992 participants screened and 620 participants enrolled (584 in nonopioid cohort and 36 in opioid cohort). INTERVENTIONS: Erenumab, 70 mg, 140 mg, or placebo, once monthly for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was MOH remission at month 6. Secondary end points included change from baseline in mean monthly acute headache medication days (AHMD) at month 6 and sustained MOH remission throughout the DBTP. Safety end points were adverse events and changes in vital signs. RESULTS: The primary analysis population included 584 participants in the nonopioid-treated cohort with a mean age of 44 years and 482 participants were female (82.5%). Baseline demographics and disease characteristics were balanced across groups. At month 6, 134 participants in the erenumab, 140 mg group (69.1%) (odds ratio [OR], 2.01; 95% CI, 1.33-3.05; P < .001 vs placebo) and 117 in the erenumab, 70 mg group (60.3%) (OR, 1.37; 95% CI, 0.92-2.05; P = .13 vs placebo) achieved MOH remission vs 102 participants in the placebo group (52.6%). AHMD use was also reduced in the erenumab groups vs placebo. Least squares mean (standard error) change from baseline in average monthly AHMD was -9.4 (0.4) days in the erenumab, 140 mg group (difference from placebo, -2.7; 95% CI, -3.9 to -1.6; P < .001) and -7.8 (0.4) days in the erenumab, 70 mg group (difference from placebo, -1.2; 95% CI, -2.4 to -0.1; P = .03), vs -6.6 (0.4) days in the placebo group. MOH remission throughout the DBTP was sustained in 119 participants (61.3%,) 96 participants (49.5%), and 73 participants (37.6%) in the erenumab, 140 mg, 70 mg, and placebo groups, respectively. Adverse events were consistent with the known safety profile of erenumab. Treatment-emergent adverse events incidence in the combined erenumab group was 66.8% (259 participants; constipation 15.2% (59 participants) and COVID-19 13.9% (54 participants) were most common. CONCLUSIONS AND RELEVANCE: In this study, monthly, 140 mg, erenumab injections safely and effectively achieved MOH remission in patients with nonopioid CM-MOH within 6 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03971071.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Tepper SJ, Dodick DW, Lanteri-Minet M, et al. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. JAMA Neurol. 2024. PMID: 39283627. doi:10.1001/jamaneurol.2024.3043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。